Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 3/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12756823 | 0.90 | ALDH1A1 (0.45) | MAPTSMN1; SMN2 | |
| SCHEMBL12756832 | 0.88 | POLB (0.40) | MAPTPOLBSMN1; SMN2BRAFPTPN11 | |
| SCHEMBL12756807 | 0.86 | MAPT (0.44) | MAPTPOLBSMN1; SMN2BRAF | |
| SCHEMBL2180757 | 0.86 | MAPT (0.41) | MAPTPOLBSMN1; SMN2BRAFRAF1 | |
| SCHEMBL1490470 | 0.85 | ANO1 (0.41) | MAPTPOLBSMN1; SMN2PIM1PIM3 | |
| SCHEMBL12830911 | 0.85 | SMN1; SMN2 (0.47) | MAPTPOLBSMN1; SMN2BRAF | |
| SCHEMBL15480663 | 0.82 | MAPT (0.40) | MAPTPOLBSMN1; SMN2 | |
| SCHEMBL12756830 | 0.82 | MAPT (0.41) | MAPTPOLBSMN1; SMN2BRAFPTPN11 | |
| SCHEMBL12756829 | 0.81 | MAPT (0.44) | MAPTPOLBSMN1; SMN2BRAFPTPN11 | |
| SCHEMBL12414204 | 0.75 | ANO1 (0.54) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | MAPT 1478/4885POLB 4774/4885SMN1; SMN2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.